Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

WHAT'S NEW

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Feb 3 2022

Full Issue

Cutting-Edge Blood Treatment 'Cures' Cancer In Two Patients, Doctors Say

Leukemia is considered an incurable disease. Yet in the cases of two men still in remission 10 years after receiving an experimental CAR-T cell therapy, doctors are using a word rarely uttered about cancer: "cured." They caution that the treatment may not work for all patients. But the findings, just published in a study, could lead to a long-term therapy for leukemia.

Philadelphia Inquirer: A Cancer Cure? Penn Treatment Kept 2 Men’s Chronic Leukemia In Remission For A Decade

The first two recipients of a groundbreaking cancer treatment developed at the University of Pennsylvania remained cancer-free a decade later, leading researchers to utter a word that’s typically taboo in cancer circles: cure. Penn researchers in 2010 treated their first chronic lymphocytic leukemia patients with CAR-T therapy, which uses the body’s own immune system to fight cancer. In a paper published Wednesday in the journal Nature, researchers report that their first two patients were still cancer-free 10 years after their treatment. What’s more, the cells were still present, protecting against future lymphoma invaders. (Gantz, 2/2)

AP: Doctors: Cancer Patients Cured A Decade After Gene Therapy

In 2010, doctors treated Doug Olson’s leukemia with an experimental gene therapy that transformed some of his blood cells into cancer killers. More than a decade later, there’s no sign of cancer in his body. The treatment cured Olson and a second patient, according to the University of Pennsylvania doctors, who said it was the first time the therapy had been studied for so long. “I’m doing great right now. I’m still very active. I was running half marathons until 2018,” said Olson, 75, who lives in Pleasanton, California. “This is a cure. And they don’t use the word lightly.” (Ungar, 2/2)

Stat: Researchers Label Early CAR-T Cancer Therapy Patient 'Cured'

“It was, at the time, an idea way out there,” Carl June, an immunologist at the University of Pennsylvania and the senior researcher on the experiment, said in a call Tuesday with reporters. “In the informed consent document that Doug signed, we thought [the CAR-T cells] would be gone in a month or two.” But as the researchers tracked Olson and another patient, what they saw was remarkable: Year after year, the CAR-T cells persisted, actively watching for cancer cells. Olson has now been cancer-free for a decade, June and his colleagues reported Wednesday in Nature. The results are so enduring that June dared to use a word that oncologists are usually loath to say: cured. (Chen, 2/2)

CNN: T-Cell Immunotherapy Tied To 10-Year Remission In Two Leukemia Patients, Study Finds

Based on the study results, "we can now conclude that CAR-T cells can actually cure patients with leukemia," June said. The CAR-T cells are an immunotherapy treatment designed to treat leukemia by harnessing the body's own immune system to target the cancer. The therapy sends a patient's immune cells to a lab to be genetically modified using a virus and gives the cells the ability to recognize and kill the source of the cancer. (Howard and Hassan, 2/2)

USA Today: After A Decade, Blood Cancer Treatment Deemed A 'Cure' In Two Patients

"Oncologists, cancer doctors, researchers don't use words like 'cure' lightly or easily or frankly very often," said Dr. Doug Porter, who treated Olson for his leukemia. "We really believe we can start to use the word 'cure.' "Others are stopping short of that word but remain impressed by the promise of so-called CAR-T cells, a "living drug" that has now been given to tens of thousands of patients, regularly providing extra years of healthy life. In a study published Wednesday in the journal Nature, the Penn team showed that CAR-T cells given to Olson and another patient, William Ludwig, in 2010 were still present. In a dish those cells were still able to kill leukemia cells. (Weintraub, 2/2)

The New York Times: A Cancer Treatment Makes Leukemia Vanish, But Creates More Mysteries 

Although most patients will not do as well, the results hold out hope that, for some, their cancer will be vanquished. But mysteries remain. The treatment involves removing T cells, white blood cells that fight viruses, from a patient’s blood and genetically engineering them to fight cancer. Then the modified cells are infused back into a patient’s circulation. (Kolata, 2/2)

Also —

Stat: With Cancer Biomarkers, Experts Say The Future Has Finally Arrived 

Back in 2000, when President Clinton called a tie in the race to map the human genome, scientists forecasted a medicinal revolution, one in which scientists could ferret out the genetic roots of every known cancer and match patients with personalized treatments. That did not happen, for reasons of biological complexity, technological immaturity, and perhaps a little scientific hubris. But after two decades of mapping the kaleidoscopic details of human DNA, researchers believe they finally have the tools and techniques to live up to those lofty promises. (Garde, 2/2)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF